TAK — Takeda Pharmaceutical Company L

Is TAK overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Overbought As of July 5, 2026

Takeda Pharmaceutical Company L (TAK) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $16.77. The rating moved from Neutral to Overbought on July 2, 2026 and has changed 28 times in the last 90 days.

Public ratingOverbought (as of July 5, 2026)
Last close$16.77
Rating changesRating changed 28 times in the last 90 days
Last changeMoved from Neutral to Overbought on July 2, 2026
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Latest MarketMoodz coverage

Takeda Expands AI Drug-Discovery Deal with Insilico ($600M)2026-07-02
Takeda’s AI-Designed Zasocitinib Tops Sotyktu in Phase 32026-06-11
Takeda Faces Up to $2.65B After $884.9M Amitiza Verdict2026-05-19
Axsome Wins FDA Nod For Auvelity Expansion in Alzheimer's Agitation2026-05-01
Axsome Nets Global Rights to Takeda's Balipodect, Expands Schizophrenia Pipeline2026-04-01

See today's live rating, score and targets

Members see the live hourly rating for TAK — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.